Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed

Clinical Infectious Diseases

Volumn 54, Issue 1, 2012, Pages 33-42

  Hermos, John A ^a,b   Young, Melissa M ^a   Fonda, Jennifer R ^a   Gagnon, David R ^a,c   Fiore, Louis D ^a,b   Lawler, Elizabeth V ^a,d  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; SEDATIVE AGENT; TRANQUILIZER;

AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMENTIA; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HEALTH CARE SYSTEM; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; VETERAN;

AGED; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ENGLAND; PNEUMONIA; PNEUMONIA, BACTERIAL; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VETERANS;

EID: 84555170756     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir767     Document Type: Article

References (34)

1. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Amer J Med 1985; 78:32-7. (Pubitemid 15036955)
2. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-24.
3. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalization for pneumonia among persons aged 65 and older in the United States, 1988-2002. JAMA 2005; 294:2712-19. (Pubitemid 41770100)
4. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections: a perspective. Ann Intern Med 1973; 78:271-6.
5. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 1996; 39:54-9. (Pubitemid 26239105)
6. Brummer RJ, Stockburgger RW. Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. Dig Dis Sci 1996; 41:2048-54.
7. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4:50-4.
8. Moss SF, Armstrong D, Arnold R, et al. GERD 2003: a consensus on the way ahead. Digestion 2003; 67:111-7. (Pubitemid 36829075)
9. Katz PO, Zavala S. Proton pump inhibitors in the management of GERD. J Gastrointest Surg 2010; 14(Suppl 1):S62-6.
10. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98:51-8. (Pubitemid 36135169)
11. Gregor JC. Acid suppression and pneumonia: a clinical indication for rational prescribing. JAMA 2004; 292:2012-3. (Pubitemid 39411212)
12. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 2009; 104(Suppl 2):S27-32.
13. Yang Y, Metz DC. Reviews in basic and clinical gastroenterology and hepatology: safety of proton pump inhibitor exposure. Gastroenterology 2010; 139:1115-27.
14. Laheij RJ, Sturkenboom MC, Hassing RJ, Deileman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955-60. (Pubitemid 39411203)
15. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007; 167:950-5.
16. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based casecontrol study. Pharmacoepidemiol Drug Saf 2009; 18:269-75.
17. SarkarM, Hennessey S, Yang Y. Proton pump inhibitor use and the risk of community-acquired pneumonia. Ann Intern Med 2008; 149:391-9.
18. Gau G, Acharya U, Khan S, Heh V, Mody L, Kao T. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10:45-52.
19. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19:792-802.
20. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and metaanalysis of clinical trials. Can J Gastroenterol 2008; 22:761-6.
21. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008; 31:627-36. (Pubitemid 351861955)
22. Herzig SJ, Howell MD, Ngo LH, Marcantinio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301:2120-8.
23. Loeb M. Pneumonia in older persons. Clin Infect Dis 2003; 37:1335-9. (Pubitemid 37433630)
24. Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer's Disease and association with negative health outcomes. Am J Manag Care 2009; 15:481-8.
25. Trifiro G, Gambassi G, Sen EF, et al. Association of communityacquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med 2010; 152:418-25.
26. Hogan WJ. Spectrum of supra-esophageal complications of gastroesophageal reflux disease. Amer J Med 1997; 103:77S-83S. (Pubitemid 28020890)
27. Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration: a study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976; 69:512-5.
28. Niedermann MS, Mandell LA, Anzueto A, et al. American Thoracic Society Guidelines for the management of adults with communityacquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-54. (Pubitemid 32578779)
29. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-95. (Pubitemid 41817660)
30. Lowe DO, Mamdani MM, Kopp A, Low DE. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease: a population based study. Clin Infect Dis 2006; 43:1272-6. (Pubitemid 44706452)
31. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and the risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170:772-8.
32. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047-56. (Pubitemid 47301504)
33. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitors therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104:1130-4.
34. Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008; 53:394-8. (Pubitemid 351170039)